Merck, wading even further into rare disease, inks $11.5B deal for Acceleron and its potential PAH blockbuster
The acquisition doesn’t come at much of a premium: Shares of $XLRN closed Wednesday at around $175, suspiciously plummeting from a high of around $186 earlier in the day. The company’s stock had ticked up for days after reports from Bloomberg and the Wall Street Journal quoting insider sources mostly outlined the terms of the deal with Merck.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.